Related Experiment Videos
Eosinophilic pneumonia due to duloxetine
Vidal J Espeleta1, William H Moore2, Philip B Kane3
1Division of Pulmonary/Critical Care Medicine,Stony Brook University, Stony Brook, NY.
Chest
|March 16, 2007
Summary
This case report details a rare instance of drug-induced pulmonary infiltrates with eosinophilia (PIEs) caused by duloxetine. The patient
Area of Science:
- Pulmonology
- Pharmacology
- Internal Medicine
Background:
- Drug-induced pulmonary infiltrates with eosinophilia (PIEs) are uncommon adverse drug reactions.
- Eosinophilic pneumonia can manifest with diverse clinical presentations.
Observation:
- A 32-year-old man presented with persistent fever, chills, and cough unresponsive to antibiotics.
- Chest imaging revealed migrating peripheral upper lobe infiltrates and bronchoscopy showed eosinophil-rich mucus.
- Peripheral eosinophilia was noted on complete blood count.
Findings:
- Transbronchial biopsy confirmed eosinophilic pneumonia.
- Cessation of duloxetine led to the reversal of symptoms, eosinophilia, and radiographic abnormalities.
- This is the first reported case of PIEs attributed to duloxetine.
Implications:
- Highlights duloxetine as a potential cause of drug-induced eosinophilic pneumonia.
- Emphasizes the importance of considering medication history in patients with unexplained pulmonary infiltrates and eosinophilia.
- Suggests prompt drug withdrawal for managing PIEs.
Related Concept Videos
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:13Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
01:19Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms: